Exploring stereoselective excretion and metabolism studies of novel 2-(2-hydroxypropanamido)-5-trifluoromethyl benzoic acid enantiomers

R-/S-2-(2-Hydroxypropanamido)-5-trifluoromethyl benzoic acid (R-/S-HFBA), as a novel COX inhibitor, was firstly reported to have remarkable anti-inflammatory and antiplatelet aggregation activities by our group. In our previous study, stereoselective differences in pharmacokinetics were found betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Rong, Rong, Zhang, Qi-li, Zhang, Rui-zhen, Dan, Yu-han, Wang, Xin, Zhao, Yun-li, Yu, Zhi-guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055496/
https://www.ncbi.nlm.nih.gov/pubmed/35516918
http://dx.doi.org/10.1039/d0ra03500a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055496/
https://www.ncbi.nlm.nih.gov/pubmed/35516918
http://dx.doi.org/10.1039/d0ra03500a

Ejemplares similares